Conflicts seen on guidelines panel

Share this article:

The AHA/ACC panel that wrote the potentially practice-changing cholesterol guidelines issued last month included six members with ties to drugmakers that sell or are developing lipid medications, Pharmalot reported. Each disclosed they worked as a consultant and received funding for personal research.

Among the 10 expert reviewers, half listed consulting relationships with such companies cited as Merck, Amgen, AstraZeneca, Pfizer, Amarin, Roche and Abbott Laboratories, whose cholesterol pills are sold by AbbVie. An AHA spokeswoman responded that none of the ACC/AHA expert reviewers had “relevant” relationships with industry.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?